M E Gleave

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

M. Gleave, S. Goldenberg, N. Bruchovsky, 1995, Urology.

Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.

M. Gleave, N. Bruchovsky, J. Crook, 2000, Molecular urology.

Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP*

M. Gleave, P. Lange, N. Sato, 1997, The Journal of Biological Chemistry.

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

M. Gleave, A. Tolcher, K. Chi, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.